Identification and verification of the temozolomide resistance feature gene DACH1 in gliomas

The most important chemotherapy treatment for glioma patients is temozolomide. However, the development of drug resistance severely restricts the use of temozolomide. Therefore, elucidating the mechanism of temozolomide resistance, enhancing temozolomide sensitivity, and extending patient survival are urgent tasks for researchers.Temozolomide resistance hub differential genes were identified using differential analysis and protein interaction analysis from the GEO datasets (GSE100736 and GSE113510). These genes were further studied in glioma patients treated with temozolomide in the TCGA and CGGA databases. Patients from the mRNAseq_325 dataset (CGGA) were considered as the training set to construct a risk model for predicting glioma sensitivity to temozolomide, while patients from the mRNAseq_693 dataset (CGGA) and TCGA-GBM dataset were considered as the validation set to evaluate the performance of models. PCR and western blot were performed to determine the difference in expression of the feature gene DACH1 between glioma cells and temozolomide-resistant glioma cells. The alterations in the sensitivity of tumor cells to temozolomide were also observed after DACH1 was silenced. The patients were then divided into two groups based on the expression of DACH1, and the differences in patient survival rates, molecular pathway activation, and level of immune infiltration were compared.Based on four signature genes (AHR, DACH1, MGMT, and YAP1), a risk model for predicting glioma sensitivity to temozolomide was constructed, and the results of timeROC in both the training and validation sets showed that the model had good predictive performance. The expression of the signature gene DACH1 was significantly downregulated in temozolomide-resistant cells, according to the results of the PCR and western blot experiments. The sensitivity of tumor cells to temozolomide was significantly reduced after DACH1 was silenced. DACH1 probably regulates temozolomide resistance in glioblastoma through the transcriptional dysregulation in cancer and ECM.This study constructs a risk model that can predict glioma susceptibility to temozolomide and validates the function of the feature gene DACH1, which provides a promising target for the research of temozolomide resistance.

[1]  J. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019. , 2022, Neuro-oncology.

[2]  S. Capuani,et al.  The Validity of Machine Learning Procedures in Orthodontics: What Is Still Missing? , 2022, Journal of personalized medicine.

[3]  Bowen Li,et al.  DACH1 inhibits breast cancer cell invasion and metastasis by down-regulating the transcription of matrix metalloproteinase 9 , 2021, Cell Death Discovery.

[4]  Arunandan Kumar,et al.  Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[5]  K. Yadav,et al.  Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[6]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[7]  G. S. Zamudio,et al.  Novel gene signatures for stage classification of the squamous cell carcinoma of the lung , 2021, Scientific Reports.

[8]  Tianzhi Huang,et al.  The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma , 2021, Cells.

[9]  Nadezhda T. Doncheva,et al.  The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets , 2020, Nucleic Acids Res..

[10]  Leili Shahriyari,et al.  A review of digital cytometry methods: estimating the relative abundance of cell types in a bulk of cells , 2020, Briefings Bioinform..

[11]  W. Yung,et al.  Molecular Mechanisms of Treatment Resistance in Glioblastoma , 2020, International journal of molecular sciences.

[12]  Raymond Y Huang,et al.  Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. , 2020, Neuro-oncology.

[13]  David T. W. Jones,et al.  cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation , 2019, Acta Neuropathologica.

[14]  E. Nafziger,et al.  Evidence-Based Practice: Temozolomide Beyond Glioblastoma , 2019, Current Oncology Reports.

[15]  V. Puduvalli,et al.  Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review , 2019, Cancers.

[16]  G. Reifenberger,et al.  cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” , 2018, Acta Neuropathologica.

[17]  H Asadi,et al.  eDoctor: machine learning and the future of medicine , 2018, Journal of internal medicine.

[18]  N. Butowski,et al.  Primary brain tumours in adults , 2018, The Lancet.

[19]  Anping Li,et al.  DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis , 2018, Journal of Hematology & Oncology.

[20]  H. Colman,et al.  Glioma Subclassifications and Their Clinical Significance , 2017, Neurotherapeutics.

[21]  Sang Y Lee.  Temozolomide resistance in glioblastoma multiforme , 2016, Genes & diseases.

[22]  Kongming Wu,et al.  The DACH/EYA/SIX gene network and its role in tumor initiation and progression , 2016, International journal of cancer.

[23]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[24]  Robert G. Ramsay,et al.  Directly targeting transcriptional dysregulation in cancer , 2015, Nature Reviews Cancer.

[25]  G. Mardon,et al.  Molecular and Cellular Pathobiology the Endogenous Cell-fate Factor Dachshund Restrains Prostate Epithelial Cell Migration via Repression of Cytokine Secretion via a Cxcl Signaling Module , 2022 .

[26]  Kongming Wu,et al.  DACH1 is a novel predictive and prognostic biomarker in hepatocellular carcinoma as a negative regulator of Wnt/β-catenin signaling , 2015, Oncotarget.

[27]  H. Wu,et al.  DACH1 inhibits SNAI1-mediated epithelial–mesenchymal transition and represses breast carcinoma metastasis , 2015, Oncogenesis.

[28]  Hua Wu,et al.  DACH1 inhibits cyclin D1 expression, cellular proliferation and tumor growth of renal cancer cells , 2014, Journal of Hematology & Oncology.

[29]  D. Placantonakis,et al.  Brain stem cells as the cell of origin in glioma. , 2014, World journal of stem cells.

[30]  S. Ishikawa,et al.  Homozygously deleted gene DACH1 regulates tumor-initiating activity of glioma cells , 2011, Proceedings of the National Academy of Sciences.

[31]  Ales Cvekl,et al.  DACH1 Is a Cell Fate Determination Factor That Inhibits Cyclin D1 and Breast Tumor Growth , 2006, Molecular and Cellular Biology.

[32]  G. Mardon,et al.  Dach1 Mutant Mice Bear No Gross Abnormalities in Eye, Limb, and Brain Development and Exhibit Postnatal Lethality , 2001, Molecular and Cellular Biology.